-
Oral Antidepressants for Reduction in Suicidality Could Deliver New Standard of Care for Bipolar Depression: NASDAQ NRXP
30 Apr 2024 15:07 GMT
Revolutionizing Bipolar Depression Treatment: The Potential of Oral Antidepressants: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
WILMINGTON, DELAWARE, UNITED STATES, April 30, 2024 /EINPresswire.com/ -- …
-
New Data on Infection Avoidance and Development of pH Neutral Ketamine, for Intravenous & Subcutaneous Use NASDAQ: NRXP
17 Apr 2024 14:57 GMT
NRx Pharmaceuticals Unveils New Data on Infection Avoidance and pH Neutral Ketamine Development: (Nasdaq: NRXP)
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
WILMINGTON, DELAWARE, UNITED STATES , April 17, 2024 /EINPresswire.com/ -- New Data on …
-
Strong Q4 Results and Milestones Announced Including Approved Stock Dividend & 8 Million More in Capital: (Nasdaq: NRXP)
01 Apr 2024 19:03 GMT
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Strong Q4 Results and Milestones Achieved
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
WILMINGTON, DELAWARE, UNITED STATES , April 1, 2024 /EINPresswire.com/ -- Strong Q4 Results and Milestones Announced …
-
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
14 Apr 2023 00:45 GMT
REYKJAVIK, Iceland, April 14, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug …
-
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
07 Dec 2022 09:00 GMT
Hukyndra® (adalimumab) launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe Follows initial introduction of Hukyndra in nine countries: …
-
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
10 Nov 2022 09:00 GMT
Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02
The switching study was conducted to investigate the pharmacokinetics, immunogenicity, efficacy and safety in patients undergoing repeated …
-
Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®
22 Sep 2022 12:00 GMT
Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab
Exclusive partnership between Alvotech and STADA in Europe includes Hukyndra® and six biosimilar candidates
REYKJAVIK, Iceland and BAD VILBEL, …